PL1653943T6 - Pochodne katecholu do leczenia raka - Google Patents

Pochodne katecholu do leczenia raka

Info

Publication number
PL1653943T6
PL1653943T6 PL04777151T PL04777151T PL1653943T6 PL 1653943 T6 PL1653943 T6 PL 1653943T6 PL 04777151 T PL04777151 T PL 04777151T PL 04777151 T PL04777151 T PL 04777151T PL 1653943 T6 PL1653943 T6 PL 1653943T6
Authority
PL
Poland
Prior art keywords
alkyl
medicament
cancer
treatment
aryl
Prior art date
Application number
PL04777151T
Other languages
English (en)
Other versions
PL1653943T3 (pl
Inventor
John C Reed
Maurizio Pellecchia
Original Assignee
The Burnham Inst La Jolla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Burnham Inst La Jolla filed Critical The Burnham Inst La Jolla
Publication of PL1653943T3 publication Critical patent/PL1653943T3/pl
Publication of PL1653943T6 publication Critical patent/PL1653943T6/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL04777151T 2003-06-25 2004-06-25 Pochodne katecholu do leczenia raka PL1653943T6 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48288603P 2003-06-25 2003-06-25
EP04777151A EP1653943B3 (en) 2003-06-25 2004-06-25 Catechol derivatives for the treatment of cancer
PCT/US2004/020569 WO2005009434A2 (en) 2003-06-25 2004-06-25 Compounds and methods for inducing apoptosis in cancer cells

Publications (2)

Publication Number Publication Date
PL1653943T3 PL1653943T3 (pl) 2008-09-30
PL1653943T6 true PL1653943T6 (pl) 2009-02-27

Family

ID=34102647

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04777151T PL1653943T6 (pl) 2003-06-25 2004-06-25 Pochodne katecholu do leczenia raka

Country Status (13)

Country Link
US (3) US7812058B2 (pl)
EP (2) EP1653943B3 (pl)
JP (2) JP2007524633A (pl)
AT (2) ATE478663T1 (pl)
AU (1) AU2004258867B2 (pl)
CA (1) CA2529507C (pl)
DE (2) DE602004028880D1 (pl)
DK (1) DK1653943T4 (pl)
ES (2) ES2303096T7 (pl)
PL (1) PL1653943T6 (pl)
PT (1) PT1653943E (pl)
SI (1) SI1653943T1 (pl)
WO (1) WO2005009434A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
WO2003038060A2 (en) * 2001-11-01 2003-05-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at bcl-2
PT1653943E (pt) * 2003-06-25 2008-05-23 Burnham Inst Derivados de catecol para o tratamento do cancro
KR20080097496A (ko) * 2004-03-25 2008-11-05 더 리젠츠 오브 더 유니버시티 오브 미시간 고시폴 공결정 및 그의 용도
US20060144723A1 (en) * 2004-11-02 2006-07-06 Mary Fuller Device for securing valuables
JP5406194B2 (ja) * 2007-10-01 2014-02-05 アセンタ セラピューティックス インコーポレイティッド Ｒ−ゴシポールｌ−フェニルアラニノールジエナミンを調製するための方法
US9115061B2 (en) 2007-10-19 2015-08-25 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
FR2924712B1 (fr) * 2007-12-06 2012-12-21 Univ Maine Derives du gossypol et de l'apogossypol, leurs preparations et leurs applications
GB0725077D0 (en) * 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
WO2009126172A1 (en) * 2008-04-11 2009-10-15 The Trustees Of Columbia University In The City Of New York Resistance to polyphenon e due to increased bcl-2 expression
WO2010019914A2 (en) * 2008-08-14 2010-02-18 The Uab Research Foundation Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
US8487131B2 (en) 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
EP2418942B1 (en) 2009-04-15 2017-08-23 Sanford-Burnham Medical Research Institute Naphthalene-based inhibitors of anti-apoptotic proteins
WO2011017096A2 (en) * 2009-08-04 2011-02-10 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
MX2012004064A (es) 2009-10-08 2012-06-08 Sanford Burnham Med Res Inst Derivados apogosipolona como agentes antineoplasicos.
US9862746B2 (en) 2013-02-15 2018-01-09 The Regents Of The University Of Michigan Compositions and methods relating to hindering DOT1L recruitment by MLL-fusion proteins
US9180226B1 (en) 2014-08-07 2015-11-10 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US9655998B2 (en) 2014-08-07 2017-05-23 Cook Medical Technologies Llc Encapsulated drug compositions and methods of use thereof
US11241520B2 (en) 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
RU2654711C1 (ru) * 2017-07-10 2018-05-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, обладающее апоптоз-индуцирующей активностью
US10945489B2 (en) * 2018-04-20 2021-03-16 Nike, Inc. Sole structure with plates and intervening fluid-filled bladder and method of manufacturing
CN110128290B (zh) * 2019-05-10 2022-04-29 江苏耐雀生物工程技术有限公司 红倍酚苯甲酰肼衍生物、中间体、制备方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US5804567A (en) 1996-07-18 1998-09-08 Cancer Institute (Hospital), Chinese Academy Of Medical Sciences Method of increasing the effectiveness of anti-metabolites
JPH1036260A (ja) * 1996-07-18 1998-02-10 Mitsui Norin Kk 抗ガン剤の効力増強方法
US6428818B1 (en) 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
JP2005502579A (ja) * 2000-12-15 2005-01-27 ワックヴォム リミテッド 新生血管形成に関連する状態を処置するための方法および組成物
NZ529792A (en) * 2001-05-30 2007-04-27 Univ Michigan Small molecule antagonists of Bcl-2 family proteins
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
PT1653943E (pt) * 2003-06-25 2008-05-23 Burnham Inst Derivados de catecol para o tratamento do cancro

Also Published As

Publication number Publication date
EP1938816A3 (en) 2008-08-06
JP2012025767A (ja) 2012-02-09
ATE387911T1 (de) 2008-03-15
JP2007524633A (ja) 2007-08-30
DE602004028880D1 (de) 2010-10-07
AU2004258867A1 (en) 2005-02-03
ES2351581T3 (es) 2011-02-08
EP1938816B1 (en) 2010-08-25
DK1653943T4 (da) 2008-12-01
DE602004012279T3 (de) 2010-07-15
EP1653943B1 (en) 2008-03-05
PL1653943T3 (pl) 2008-09-30
SI1653943T1 (sl) 2008-08-31
WO2005009434A2 (en) 2005-02-03
US20110111057A1 (en) 2011-05-12
US7812058B2 (en) 2010-10-12
CA2529507A1 (en) 2005-02-03
US20120269901A1 (en) 2012-10-25
US20050027000A1 (en) 2005-02-03
EP1653943A2 (en) 2006-05-10
DE602004012279D1 (de) 2008-04-17
CA2529507C (en) 2011-08-09
DK1653943T3 (da) 2008-06-23
EP1653943B3 (en) 2008-07-30
ES2303096T7 (es) 2009-06-18
WO2005009434A3 (en) 2005-06-09
DE602004012279T9 (de) 2010-01-28
US8367644B2 (en) 2013-02-05
ES2303096T3 (es) 2008-08-01
PT1653943E (pt) 2008-05-23
ATE478663T1 (de) 2010-09-15
EP1938816A2 (en) 2008-07-02
AU2004258867B2 (en) 2010-02-18
DE602004012279T2 (de) 2009-07-16

Similar Documents

Publication Publication Date Title
PT1653943E (pt) Derivados de catecol para o tratamento do cancro
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
TNSN04065A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
TWI255807B (en) Therapeutic agents
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
GB0318447D0 (en) Therapeutic agents
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
UA89035C2 (ru) Эфиры гидроксамовых кислот и их фармацевтическое применение
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
DE60014916D1 (de) Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
PL342614A1 (en) Anticarcinogenic drugs
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.
TW200510384A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
WO2002074756A3 (de) Urokinase-inhibitoren
SE0201837D0 (sv) Chemical compounds
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
WO2003095453A1 (fr) Composes a activite antihelicobacter
SE0103272D0 (sv) Chemical compounds
MXPA05013717A (es) Derivados de acido 2-etoxi-2-fenilpropionico para el tratamiento de trastornos de lipido.
AP2002002669A0 (en) Hygromycin a derivatives for the treatment of bacterial and protozoal infections.
MXPA06000651A (es) Uso de derivados de indazol para el tratamiento de dolor neuropatico.